MaxCyte
MaxCyte have a passion for the discovery, development and manufacturing of next-generation therapies, harnessing the power of living cells to transform lives.
Latest Content
Product News
MaxCyte® Acquires SeQure Dx To Broaden Cell Engineering Offerings With On-Target and Off-Target Editing Assessments
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a cell-engineering focused company announced the acquisition of SeQure Dx.
Industry Insight
The Rise of Cell and Gene Therapies in Treating Complex Diseases
Cell and gene therapies are revolutionizing medicine. Looking to 2025, advancements in allogeneic therapies, streamlined autologous processes and broader applications promise increased accessibility and innovation in treating complex diseases.
Product News
MaxCyte Signs Strategic Platform License With Kamau Therapeutics To Accelerate the Development of Cell Therapies for Genetic Diseases
Kamau to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair (HDR) novel gene correction technology.
Product News
MaxCyte Signs Strategic Platform License With Prime Medicine To Advance Next-Generation Gene Editing Therapies
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), announced the signing of a strategic partnership with Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies.
Article
Embracing Diversity To Advance Science and Clinical Care
Variation is a powerful force in biology. This article explores the importance of moving away from one-size-fits-all approaches and towards diversifying cell lines and clinical trials.
Product News
MaxCyte Signs Strategic Platform License With Curamys To Enable Cell and Gene Therapies for the Treatment of Rare Intractable Diseases
Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
Industry Insight
Exploring Flow Electroporation for Cell Engineering
Technology Networks spoke to Dr. Cenk Sumen, chief scientific officer of MaxCyte, about their pioneering cell engineering platform.
Product News
MaxCyte Signs Strategic Platform License With LG Chem To Advance its Allogeneic CAR-T Programs
MaxCyte, Inc. has announced the signing of a strategic platform license with LG Chem Ltd.
Advertisement
